BAY 11-7082: An Anti-inflammatory Drug for COVID-19

被引:0
|
作者
Nemati, Mohadeseh [1 ]
Pouya, Fahima Danesh [1 ]
Asl, Elmira Roshani [1 ]
Rasmi, Yousef [1 ,2 ]
机构
[1] Urmia Univ Med Sci, Fac Med, Dept Biochem, Orumiyeh, Iran
[2] Urmia Univ Med Sci, Cellular & Mol Res Med Inst, Cellular & Mol Res Ctr, Orumiyeh, Iran
来源
SUDAN JOURNAL OF MEDICAL SCIENCES | 2023年 / 18卷 / 01期
关键词
BAY; 11-7082; COVID-19; PAK1; INHIBITORS;
D O I
10.18502/sjms.v18i1.12872
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new coronavirus named by the International Committee on Taxonomy of Viruses. COVID-19 patients have high mortality due to respiratory failure from acute respiratory distress syndrome (ARDS) induced by SARS-CoV-2. The abnormal activation of P21-activated kinase (PAK1, RAC/CDC42-activated kinase 1) is reported in COVID-19. The PAK1 induces nuclear factor kappa B (NF-?B) activation as well as inflammatory pathways through its stimulation. BAY 11-7082 {(E) 3-[(4-methylphenyl)-sulfonyl]-2-propenenitrile is one of the therapies that inhibit inflammation via mentioned signaling pathway, therefore, we suggest that this drug can potentially be effective in treating COVID-19.
引用
收藏
页码:117 / 120
页数:4
相关论文
共 50 条
  • [41] Bay 11-7082, a NF-KB inhibitor reverses functional and sensorimotor deficits in experimental diabetic neuropathy
    Kumar, A.
    Sharma, S. S.
    INDIAN JOURNAL OF PHARMACOLOGY, 2008, 40 : 213 - 214
  • [42] The NFκB Pathway Inhibitors Bay 11-7082 and Parthenolide Induce Programmed Cell Death in Anucleated Erythrocytes
    Ghashghaeinia, Mehrdad
    Toulany, Mahmoud
    Saki, Mohammad
    Bobbala, Diwakar
    Fehrenbacher, Birgit
    Rupec, Rudolf
    Rodemann, H. Peter
    Ghoreschi, Kamran
    Roecken, Martin
    Schaller, Martin
    Lang, Florian
    Wieder, Thomas
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2011, 27 (01) : 45 - 54
  • [43] Prostaglandins and non-steroidal anti-inflammatory drugs in Covid-19
    Al-Kuraishy, Hayder M.
    Al-Gareeb, Ali, I
    Al-Maiahy, Thabat J.
    Alexiou, Athanasios
    Mukerjee, Nobendu
    Batiha, Gaber El-Saber
    BIOTECHNOLOGY AND GENETIC ENGINEERING REVIEWS, 2022, 40 (04) : 3305 - 3325
  • [44] Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19
    Moutsopoulos, Haralampos M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (09) : 1253 - +
  • [45] Anti-inflammatory effects of GLP-1 in patients with COVID-19
    Sazgarnejad, Saharnaz
    Yazdanpanah, Niloufar
    Rezaei, Nima
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2022, 20 (03) : 373 - 381
  • [46] Perioperative Nonsteroidal Anti-Inflammatory Agents in the COVID-19 Orthopedic Patient
    Wu, Christopher L.
    Jules-Elysee, Kethy M.
    Kirksey, Meghan A.
    Liguori, Gregory A.
    HSS JOURNAL, 2020, 16 (1_SUPPL) : 97 - 101
  • [47] A Case of COVID-19 with Acute Exacerbation after Anti-Inflammatory Treatment
    Ashino, Yugo
    Shirato, Yoichi
    Yaegashiwa, Masahiro
    Yamanouchi, Satoshi
    Miyakawa, Noriko
    Ando, Kokichi
    Sakurada, Yumiko
    Yasutan, Haorile Chagan
    Hattori, Toshio
    REPORTS, 2022, 5 (02)
  • [48] Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19
    Robb, Calum T.
    Goepp, Marie
    Rossi, Adriano G.
    Yao, Chengcan
    BRITISH JOURNAL OF PHARMACOLOGY, 2020, 177 (21) : 4899 - 4920
  • [49] Correspondence on 'Anti-inflammatory therapy for COVID-19 infection: the case for colchicine'
    Perricone, Carlo
    Bartoloni, Elena
    Cafaro, Giacomo
    Caporali, Roberto
    Gerli, Roberto
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (04)
  • [50] Antibiotics with Antiviral and Anti-Inflammatory Potential Against Covid-19: A Review
    Abadi, Banafshe
    Ilaghi, Mehran
    Shahsavani, Yasamin
    Faramarzpour, Mahsa
    Oghazian, Mohammad Bagher
    Rahimi, Hamid-Reza
    CURRENT REVIEWS IN CLINICAL AND EXPERIMENTAL PHARMACOLOGY, 2023, 18 (01) : 51 - 63